Logo for NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals Investor Relations Material

Latest events

Logo for NGM Biopharmaceuticals Inc

Study Result

NGM Biopharmaceuticals
Logo for NGM Biopharmaceuticals

Q4 2023

11 Mar, 2024
Logo for NGM Biopharmaceuticals

Corporate Presentation

9 Jan, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from NGM Biopharmaceuticals Inc

Access all reports
NGM Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of liver and metabolic diseases, retinal diseases, and cancer. The company's key products in development include NGM707, a dual antagonist monoclonal antibody for advanced metastatic solid tumors, and Aldafermin, an engineered analog of a human hormone aimed at treating liver diseases such as non-alcoholic steatohepatitis. Additionally, NGM Biopharmaceuticals works on a variety of other drug candidates targeted at different therapeutic areas, using a biologics-based platform to create and evaluate monoclonal antibodies and other proteins. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.